Maravai LifeSciences (MRVI) Insider Award Boosts Stake to 169,907 Shares

Rhea-AI Filing Summary

Maravai LifeSciences Holdings (MRVI) – Director Equity Grant

Form 4 filed 06/18/2025 shows director Susannah Gray acquired 89,139 Class A common shares via restricted stock units (RSUs) granted on 06/16/2025 under the 2020 Omnibus Incentive Plan. The RSUs vest fully on the earlier of one year from grant or the 2026 annual stockholders’ meeting and carry a reference price of $2.16 per share.

Following the award, Gray’s direct beneficial ownership rises to 169,907 shares. No dispositions or derivative transactions were reported, and the filing contains no financial or operational data.

The transaction is routine, compensation-related insider acquisition rather than an open-market purchase; therefore, it signals continued alignment of director incentives with shareholders but has limited standalone market impact.

Positive

• Directoradded 89,139 shares through RSUs, increasing direct ownership to 169,907 shares, modestly aligning board and shareholder interests.

Negative

• Acquisition was a compensation grant rather than an open-market purchase, limiting the strength of the bullish insider signal.

Insights

Financial Analyst

TL;DR: Routine RSU grant; negligible valuation impact, mildly positive for alignment.

The 89,139-share RSU award lifts Gray’s stake to roughly 0.1% of diluted shares, a marginal increase that does not alter MRVI’s capital structure. Because the shares were not bought with personal funds, typical insider-buying signals do not apply. Dilution from the plan is minimal relative to MRVI’s ~255 million shares outstanding. Overall, the event is neutral for valuation and liquidity but modestly positive for governance by maintaining equity-based director compensation.

Corporate Governance Specialist

TL;DR: Standard board compensation; maintains incentive alignment, no red flags detected.

This Form 4 confirms MRVI continues to compensate directors primarily with equity, fostering long-term value focus. The single-tranche, one-year vesting aligns tenure with share performance. Absence of derivative structures or accelerated vesting clauses reduces complexity risk. From a governance standpoint, the filing is routine and non-controversial, providing transparency without materially influencing shareholder decision-making.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAY SUSANNAH

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		A		89,139(1)	A	$2.16	169,907	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Susannah Gray	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MRVI shares did director Susannah Gray acquire on 06/16/2025?

She received 89,139 restricted stock units of Class A common stock.

What is the vesting schedule for the new MRVI RSUs?

The RSUs vest in full on the earlier of one year from grant or the 2026 annual stockholders’ meeting.

What is Susannah Gray59;s total MRVI share ownership after the transaction?

Her beneficial ownership increased to 169,907 shares, held directly.

Was there any sale of MRVI shares or derivative activity reported in this Form 4?

No. No dispositions or derivative securities were reported.

Does this insider transaction materially impact MRVI59;s share count?

Impact is immaterial; the grant is minor relative to MRVI59;s total shares outstanding.